Aldo-keto reductase
From Proteopedia
(Difference between revisions)
| Line 15: | Line 15: | ||
*<scene name='49/491879/Cv/7'>NADP and polyfluorinated inhibitor are situated in the tunnel</scene>. | *<scene name='49/491879/Cv/7'>NADP and polyfluorinated inhibitor are situated in the tunnel</scene>. | ||
| + | </StructureSection> | ||
==3D structures of aldo-keto reductase== | ==3D structures of aldo-keto reductase== | ||
| Line 124: | Line 125: | ||
**[[2wzm]] – MsAKR + ligand<br /> | **[[2wzm]] – MsAKR + ligand<br /> | ||
}} | }} | ||
| + | |||
==References== | ==References== | ||
Revision as of 15:54, 28 December 2016
| |||||||||||
3D structures of aldo-keto reductase
Updated on 28-December-2016
See Hydroxysteroid dehydrogenase 20-alpha HSD
See Hydroxysteroid dehydrogenase 3-alpha HSD
See Hydroxysteroid dehydrogenase 17-alpha HSD
References
- ↑ Penning TM. The aldo-keto reductases (AKRs): Overview. Chem Biol Interact. 2015 Jun 5;234:236-46. doi: 10.1016/j.cbi.2014.09.024. Epub, 2014 Oct 7. PMID:25304492 doi:http://dx.doi.org/10.1016/j.cbi.2014.09.024
- ↑ Drury JE, Mindnich R, Penning TM. Characterization of disease-related 5beta-reductase (AKR1D1) mutations reveals their potential to cause bile acid deficiency. J Biol Chem. 2010 Aug 6;285(32):24529-37. doi: 10.1074/jbc.M110.127779. Epub 2010, Jun 3. PMID:20522910 doi:http://dx.doi.org/10.1074/jbc.M110.127779
- ↑ Cousido-Siah A, Ruiz FX, Mitschler A, Porte S, de Lera AR, Martin MJ, Manzanaro S, de la Fuente JA, Terwesten F, Betz M, Klebe G, Farres J, Pares X, Podjarny A. Identification of a novel polyfluorinated compound as a lead to inhibit the human enzymes aldose reductase and AKR1B10: structure determination of both ternary complexes and implications for drug design. Acta Crystallogr D Biol Crystallogr. 2014 Mar;70(Pt 3):889-903. doi:, 10.1107/S1399004713033452. Epub 2014 Feb 27. PMID:24598757 doi:http://dx.doi.org/10.1107/S1399004713033452
